<p>Liver disease is a severe health issue that is alarmingly common throughout the world. The current investigation sought to evaluate and compare two veterinary formulations—Dozliv Forte-P (Treatment group 1) and Dozliv Forte-P Ultra (Treatment group 2)—for their hepatoprotective potential in a carbon tetrachloride (CCl₄)-induced liver injury model. Hepatoprotective properties of both the treatment groups were evaluated in Wistar albino rats at a dosage of 0.25 ml/kg/day per os (p.o.). The level of protection was assessed by identifying the marker enzymes (SGOT, SGPT). Additionally, to assess antioxidant activity, the effects of the treatment groups on glutathione (GSH), catalase (CAT), nitrite level, and lipid peroxidation (LPO) have been estimated in liver homogenates. The biochemical markers, such as SGOT (serum glutamate-oxaloacetate transaminase) and SGPT (serum glutamate-pyruvate transaminase), which were increased by carbon tetrachloride (CCl₄) intoxication, significantly decreased in the animal groups receiving Dozliv Forte-P, Dozliv Forte-P Ultra, and Silymarin. Hepatic antioxidant enzyme levels, including GSH and catalase, dropped following CCl₄ injection, and hepatic lipid peroxidation and nitrite level increased. Therapy with Treatment group 1, Treatment group 2, and Silymarin restored normal levels of these liver antioxidant enzymes. The biochemical results were corroborated by histological investigations, and Dozliv Forte-P and Dozliv Forte-P Ultra therapies successfully demonstrated hepatoprotective potential in rats. Additionally, both Dozliv Forte-P and Dozliv Forte-P Ultra significantly decreased the CCl₄ group’s activity; but Dozliv Forte-P Ultra’s effects were more pronounced, demonstrating greater hepatoprotective efficacy.</p> Graphical abstract <p></p>